doi:10.16139/j.1007-9610.2019.03.007

[1] Partelli S, Javed AA, Andreasi V, et al.The number of positive nodes accurately predicts recurrence after pancreaticoduodenectomy for nonfunctioning neuroendocrine neoplasms[J]. Eur J Surg Oncol,2018,44(6):778-783.
[2] Fairweather M, Swanson R, Wang J, et al.Management of neuroendocrine tumor liver metastases: long-term outcomes and prognostic factors from a large prospective database[J]. Ann Surg Oncol,2017,24(8):2319-2325.
[3] Hüttner FJ, Schneider L, Tarantino I, et al.Palliative resection of the primary tumor in 442 metastasized neuroendocrine tumors of the pancreas: a population-based, propensity score-matched survival analysis[J]. Langenbecks Arch Surg,2015,400(6):715-723.
[4] Le Treut YP, Grégoire E, Klempnauer J, et al.Liver transplantation for neuroendocrine tumors in Europe-results and trends in patient selection: a 213-case European liver transplant registry study[J]. Ann Surg,2013, 257(5):807-815.
[5] Pavel M, O'Toole D, Costa F, et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial Neuroendocrine Neoplasms (NEN) and NEN of unknown primary site[J]. Neuroendocrinology,2016,103(2):172-185.
[6] Cives M, Strosberg J.The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors[J]. Drugs,2015,75(8):847-858.
[7] Rinke A, Müller HH, Schade-Brittinger C, et al.Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group[J]. J Clin Oncol,2009,27(28):4656-4663.
[8] Wang Y, Wang W, Jin K, et al.Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors[J]. Oncol Lett,2017,13(3):1165-1174.
[9] Caplin ME, Pavel M, Ćwikła JB, et al.Lanreotide in metastatic enteropancreatic neuroendocrine tumors[J]. N Engl J Med,2014,371(3):224-233.
[10] Scarpa A, Chang DK, Nones K, et al.Whole-genome landscape of pancreatic neuroendocrine tumours[J]. Nature,2017,543(7643):65-71.
[11] Yao JC, Shah MH, Ito T, et al.Everolimus for advanced pancreatic neuroendocrine tumors[J]. N Engl J Med,2011, 364(6):514-523.
[12] Raymond E, Dahan L, Raoul JL, et al.Sunitinib malate for the treatment of pancreatic neuroendocrine tumors[J]. N Engl J Med,2011,364(6):501-513.
[13] Sorbye H, Welin S, Langer SW, et al.Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma(WHO G3): the NORDIC NEC study[J]. Ann Oncol,2013,24(1):152-160.
[14] Strosberg J, El-Haddad G, Wolin E, et al.Phase 3 trial of ¹⁷⁷Lu-Dotatate for midgut neuroendocrine tumors[J]. N Engl J Med,2017,376(2):125-135.
[15] Vanderwalde A, Spetzler D, Xiao N, et al.Microsatellite instability status determined by next-generation sequen-cing and compared with PD-L1 and tumor mutational bur-den in 11,348 patients[J]. Cancer Med,2018,7(3):746-756.

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	ZHANG Hongzhan, ZHANG Kai. Current status and prospect of endoscopic photodynamic therapy for unresectable extrahepatic cholangiocarcinoma and ampullary carcinoma [J]. Journal of Surgery Concepts & Practice, 2023, 28(04): 316-320.
[2]	GAO Pan, CAI Yunqiang, PENG Bing. Function-preserving laparoscopic resection of pancreatic head and duodenal papilla tumors [J]. Journal of Surgery Concepts & Practice, 2023, 28(03): 190-196.
[3]	YU Lan, ZHANG Yongyi, HUANG Lei, WAN Xin, JIANG Shengyao, TANG Sijing, ZHANG Jun, HU Weiguo. Risk factors of severe postoperative complications in elderly patients with pancreaticoduodenectomy [J]. Journal of Surgery Concepts & Practice, 2023, 28(02): 139-146.
[4]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 1-5.
[5]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 6-10.
[6]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 14-18.
[7]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 19-21.
[8]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 25-29.
[9]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 30-33.
[10]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 34-38.
[11]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 42-45.
[12]	YANG Chunxue, XU Haimin, DA Qian. Clinicopathological features of pancreatic intraductal oncocytic papillary neoplasm: a report of 5 cases [J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 52-57.
[13]	XU Yu, ZHANG Junfeng, HUA Rong. Use of octreotide for prevention of pancreatic leak after pancreatoduodenectomy: study progress [J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 83-86.
[14]	LUO Danyang, GAO Yiming. Study on oral microflora related to pancreatic cancer [J]. Journal of Surgery Concepts & Practice, 2021, 26(01): 84-86.
[15]	DING Fangmi, LIU Zhendong. Forkhead box D1 promotes invasion and metastasis of pancreatic cancer via extracellular signal-regulated kinase pathway [J]. Journal of Surgery Concepts & Practice, 2020, 25(06): 486-492.